NFE2L2 and acute promyelocytic leukemia: In this study, we tested the NRF2 inhibitors—Apigenin, Berberine, Chrysin, and Luteolin (ABCL) for their ability to overcome doxorubicin resistance in acute promyelocytic leukemia HL-60 cells (HL-60/DOXO cells).